Erythropoietin changes contractility, cAMP, and nitrite levels of isolated rat hearts

Journal of Physiological Sciences

Volumn 56, Issue 3, 2006, Pages 247-251

  Kaygisiz, Ziya ^a   Erkasap, Nilufer ^a   Yazihan, Nuray ^b   Sayar, Kemal ^b   Ataoglu, Haluk ^b   Uyar, Ruhi ^a   Ikizler, Murat ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

cAMP; Contractility; Erythropoietin; Heart; Nitrite

Indexed keywords

CYCLIC AMP; ERYTHROPOIETIN; NITRITE; RECOMBINANT ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOSE RESPONSE; FEMALE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE CONTRACTILITY; HEART PERFUSION; HEART RATE; HEMODYNAMICS; MALE; NONHUMAN; RAT; UREA CYCLE; ANIMAL; HEART; HEART CONTRACTION; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEART; HEART RATE; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; STROKE VOLUME; TIME FACTORS;

EID: 34250712271     PISSN: 18806546     EISSN: None     Source Type: Journal    
DOI: 10.2170/physiolsci.RP004806     Document Type: Article

References (47)

1. 2+ mobilization in cultured rat vascular smooth-muscle cells. Nephrol Dial Transplant. 2001;16:491-9.
2. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res. 2003;59:538-48.
3. Bazen JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci USA. 1990;87:6934-8.
4. Fraser JK, Lin FK, Berridge MV. Expression of high affinity receptors for erythropoietin on human bone marrow cells and on the human erythroleukemic cell line, HEL. Exp Hematol. 1998;16:836-42.
5. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA. 1994;91:3974-8.
6. Westenfelder C, Biddle DL, Baranowski RL. Human, rat and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999;55:808-20.
7. Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas FJr, Tabira T, Sasaki R. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993;268:11208-16.
8. Wald M, Gutnisky A, Borda E, Sterin-Borda L. Erythropoietin modified the cardiac action of oubain in chronically anemic-uraemic rats. Nephron. 1995;71:190-6.
9. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA. 2003;100:4802-6.
10. Tramontano AF, Muniyappa R, Black AD, Blendea MC, Cohen I, Deng L, Sowers JR, Cutaia MV, El-Sherif N. Erythropoietin protects cardiac myocytes from hypoxia- induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun. 2003;308:990-4.
11. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA. 1990;87:5978-82.
12. Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell'Era P, Nico B, Roncali L, Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood. 1999;93:2627-36.
13. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin: Results of a combined Phase I and II clinical trial. N Engl J Med. 1987;316:73-8.
14. Linde T, Wikstrom B, Andersson LG, Danielson BG. Renal anemia treatment with recombinant human erythropoietin increases cardiac output in patients with ischaemic heart disease. Scand J Urol Nephrol. 1996;30:115-20.
15. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recomminant human erythropoietin on renal resistance vessels. Kidney Int. 1991;39:259-65.
16. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens. 1993;6:103-7.
17. Kuramochi, S, Sugimoto Y, Ikawa Y, Todokoro K. Transmembrane signaling during erythropoietin-and dimethyl-sulfoxide-induced erythroid cell differentiation. Eur J Biochem. 1990;193:163-8.
18. Miller BA, Foster K, Robinshaw JD, Whitfield CF, Bell L, Cheung JY. Role of pertussis toxin-sensitive guanosine triphosphate-binding proteins in the response of erythroblasts to erythropoietin. Blood. 1991;77:486-92.
19. Ostrom RS, Bundey RA, Insel PA. Nitric oxide inhibition of adenylyl cyclase type 6 activity is dependent upon lipid rafts and caveolin signaling complexes. J Biol Chem. 2004;279:19846-53.
20. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol. 1995;269:F 838-45.
21. Yang BC, Nichols WW, Mehta JL. Cardiac effects of acetylcholine in rat hearts: role of endothelium-derived relaxing factor and prostaglandins. Am J Physiol. 1993;264:H1388-93.
22. He M-X, Downey HF. Downregulation of ventricular contractile function during early ischemia is flow but not pressure dependent. Am J Physiol. 1998;275:H1520-3.
23. Liu J-X, Tanonaka K, Ohtsuka Y, Sakai Y, Takeo S. Improvement of ischemia/reperfusion- induced contractile dysfunction of perfused hearts by class Ic antiarrhythmic agents. J Pharmacol Exp Ther. 1993;266:1247-54.
24. Tunctan B, Okur H, Calsr CH, Abacoglu H, Cakc I, Kanzk I, Abacoglu N. Comparison of nitrite oxide production by monocyte/macrophages in healthy subjects and patients with active pulmonary tuberculosis. Pharmacol Res. 1998;37:219-26.
25. Ugur O, Onaran HO. Allosteric equilibrium model explains steady-state coupling of β-adrenergic receptors to adenylate cyclase in turkey erythrocyte membranes. Biochem J. 1997;323:765-76.
26. Wu XC, Johns EJ, Richards NT. Relationship between erythropoietin and nitric oxide in the contraction of rat renal arcuate arteries and human umbilical vein endothelial cells. Clin Sci (Lond). 1999;97:413-9.
27. Rudko IA, Balashova TS, Kuatiev AA, Ermolenko VM. The action of recombinant-human-erythropoietin (RHE) on platelet and red-cell function in chronic-renal-failure patients on hemodialysis. Terapevticheskii Arkhiv. 1994;66:57-60.
28. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA. 1991;88:1197-1201.
29. 2+ current. J Biol Chem. 1993;268:26286-95.
30. Wahler GM, Dollinger S. Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through c-GMP-dependent protein kinase. Am J Physiol. 1995;268:C45-54.
31. Fischmeister R, Mery PF. Regulation du courant2 calcique cardiaque par la voie du cGMP/NO. R Seances Soc Biol. 1996;190:181-206.
32. Casadei B, Sears CE. Nitric-oxide mediated regulation of cardiac contractility and stretch responses. Prog Biophys Mol Biol. 2003;82:67-80.
33. Sterin-Borda L, Barcelo AC, Bozzini CE. Erythropoietin improves cardiac contractility in post-hypoxic mice. Br J Haematol. 2003;121:180-6.
34. 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol. 1996;24:392-7.
35. Simmerman HK, Jones LR. Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev. 1998;78:921-47.
36. Kranias EG, Garvey JL, Srivastava RD, Solaro RJ. Phosphorylation and functional modifications of sarcoplasmic reticulum and myofibrils in isolated rabbit hearts stimulated with isoprenaline. Biochem J. 1985;226:113-21.
37. 2+ and phosphorylation. Science. 1995;267:1997-2000.
38. 2+ transient in rat myocytes during β-adrenergic stimulation. J Physiol. 1997;505:385-402.
39. 2+ channels: Activation by phospholipase c-γ1. Kidney Int. 1998;53:1259-68.
40. Wu XC, Richards NT, Johns EJ. The influence of erythropoietin on the vascular responses of resistance arteries. Exp Physiol. 1999;84:917-27.
41. Bode-Böger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin. J Cardiovasc Pharmacol. 1992;20:25-8.
42. Takahashi S, Yanai M, Okada K. Recombinant human erythropoietin has no direct or strong vasoconstrictor effects in vivo and in vitro. Nephrol Dial Transplant. 1995;10:815-20.
43. Tsukahara H, Hiraoka M, Hori C, Hata I, Okada T, Gejyo F, Sudo M. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rats. Scand J Clin Lab Invest. 1997;57:487-93.
44. Bund J, Heagerty A, Edmunds M, Walls J. Erythropoietin does not induce vasoconstriction directly in human subcutaneous resistance arterioles. Nephron. 1989;53:173.
45. Martin GR, Ongkingo JR, Turner ME, Skurow ES, Ruley EJ. Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease. Pediatr Nephrol. 1993;7:276-80.
46. Hoeldtke RD, Horvath GG, Bryner KD. Treatment of orthostatic tachycardia with erythropoietin. Am J Med. 1995;99:525-9.
47. Low-Friedrich I, Grutzmacher P, Marz W, Bergmann M, Schoeppe W. Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif. 1990;8:272-80.